Number of Equivalent Common Shares Issued.

No definition available.

Name:	lptx_NumberOfEquivalentCommonSharesIssued
Namespace Prefix:	lptx_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Period to held special meeting.

+ References

No definition available.

+ Details

Name:	lptx_PeriodToHeldSpecialMeeting
Namespace Prefix:	lptx_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of common shares issuable upon conversion for each share of temporary stock to be converted.

+ References

No definition available.

+ Details

Name:	lptx_TemporaryStockConvertibleConversionRatio
Namespace Prefix:	lptx_
Data Type:	xbrli:pureItemType
Balance Type:	na
Period Type:	instant

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257

+ Details

Name:	us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Number of shares of stock issued during the period pursuant to acquisitions.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682

+ Details

Name:	us-gaap_StockIssuedDuringPeriodSharesAcquisitions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_StatementClassOfStockAxis=lptx_SeriesXPreferredStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AssetAcquisitionAxis=lptx_FlameBiosciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_TitleOfIndividualAxis=lptx_FlameShareholdersMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=lptx_WarrantsToPurchaseCommonStockMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Net Loss Per Share - Antidilutive (Details)		3 Months Ended
Net Loss Per Share - Antidilutive (Details)	Jan. 17, 2023 shares	Mar. 31, 2023 shares	Mar. 31, 2022 shares	Jan. 31, 2023
Securities excluded from computation of diluted net loss per share
Anti-dilutive securities excluded from calculation of diluted net loss per share		58,434,133	48,067,787
Period to held to special meeting		6 months
Series X Preferred Stock
Securities excluded from computation of diluted net loss per share
Temporary Stock Convertible Conversion Ratio		1,000
Flame Biosciences, Inc [Member]
Securities excluded from computation of diluted net loss per share
Number of shares issued	19,729,010
Equivalent common shares	156,485,311
Period to held to special meeting		6 months
Flame Biosciences, Inc [Member] \| Series X Preferred Stock
Securities excluded from computation of diluted net loss per share
Equivalent common shares	136,248,000
Temporary Stock Convertible Conversion Ratio	1,000	1,000		1,000
Flame Biosciences, Inc [Member] \| Flame shareholders \| Series X Preferred Stock
Securities excluded from computation of diluted net loss per share
Number of shares issued		136,248
Equivalent common shares		136,248,000
Restricted stock units to purchase common stock
Securities excluded from computation of diluted net loss per share
Anti-dilutive securities excluded from calculation of diluted net loss per share		2,925,000	3,510,606
Options to purchase common stock
Securities excluded from computation of diluted net loss per share
Anti-dilutive securities excluded from calculation of diluted net loss per share		20,088,158	9,101,507
Warrants to purchase common stock
Securities excluded from computation of diluted net loss per share
Anti-dilutive securities excluded from calculation of diluted net loss per share		35,420,975	35,455,674